New neuroscience imaging reveals the biological differences between honest people and liars and why honest people sometimes ...

The price trend for Cognition Therapeutics, Inc. (CGTX) has been bearish lately and the stock has lost 9.6% over the past week. However, the formation of a hammer chart pattern in its last trading ...

And yet, I struggle with a lingering question: Is this just computation? Or are we seeing the beginnings of something ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics (CGTX – Research Report) and keeping the price ...

A species of wood-eating fungus didn’t need a brain to pass a cognitive test with flying colors, and researchers say this ...

Discovery hints at wide-ranging potential for enhancing brain function Although it is widely recognized that sleep boosts ...

Concussions affect aperiodic brain activity, a key signal often dismissed as "background noise," which plays a role in brain ...

Cognition Therapeutics (CGTX) provided an update on a biomarker analysis from the Phase 2 ‘SHINE’ study in mild-to-moderate Alzheimer’s ...

Join us for the next NAMI Ask the Expert Cognition Series! In this presentation Dr. Matcheri Keshavan will review the current ...

Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the route of ...

纽约州帕切斯 - 临床阶段生物制药公司Cognition Therapeutics, Inc. (NASDAQ: CGTX)宣布完成其2期SHIMMER研究,该研究针对CT1812用于治疗轻度至中度路易体痴呆症 (DLB)。最后一位患者访视已经结束,公司预计将于2024年12月报告该研究的初步结果。